LY2109761 is a novel transforming growth factor beta receptor type I and type II dual inhibitor. The effect of LY2109761 has been evaluated on soft agar growth, migration, invasion using a fibroblast coculture model, and detachment-induced apoptosis (anoikis) by Annexin V flow cytometric analysis. The efficacy of LY2109761 on tumor growth, survival, and reduction of spontaneous metastasis have been evaluated in an orthotopic murine model of metastatic pancreatic cancer expressing both luciferase and green fluorescence proteins (L3.6pl/GLT). In vivo, LY2109761 , in combination with gemcitabine, significantly reduced the tumor burden, prolonged survival, and reduced spontaneous abdominal metastases.
TGF-beta/Smad Inhibitors Related Products:
SB431542; LDN-193189; Galunisertib; SB525334; SB-505124; GW788388; LY364947; RepSox; K02288; A-83-01; LDN-212854; PD169316; ITD-1; LY3200882; Dorsomorphin; Dorsomorphin 2HCl; Kartogenin